Claims

1. A device for the intravaginal administration of Pritelivir.

2. The device according to claim 1, wherein Pritelivir is selected from the group comprising the free base of Pritelivir and Pritelivir mesylate salt.

3. The device according to claim 1 comprising a composition comprising the free base of Pritelivir and/or the Pritelivir mesylate salt.

4. The device according to any one of claims 1 to 3, wherein the device comprises a biostable and biocompatible polymer matrix.

5. The device according to any one of claims 1 to 4, wherein the device comprises a biostable and biocompatible polymer matrix comprising a silicone elastomer.

6. The device according to any one of claims 1 to 5, wherein the device is an intravaginal ring.

7. The device according to any one of claims 1 to 6, wherein the device is suitable for immediate release of Pritelivir.

8. The device according to any one of claims 1 to 6, wherein the device is suitable for sustained release of Pritelivir.

9. The device according to any one of claims 1 to 6, wherein the device is suitable for controlled release of Pritelivir.

10. The device according to any one of claims 1 to 6, wherein the device is suitable for immediate and sustained release of Pritelivir.

11. The device according to any one of claims 1 to 6, wherein the device is suitable for immediate and controlled sustained release of Pritelivir.

12. The device according to any one of claims 1 to 11, wherein the device comprises Pritelivir in a total amount of at least 25 mg, at least 30 mg, at least 40 mg, at least 50 mg, at least 75 mg, at least 100 mg, at least 150 mg, at least 200 mg, at least 225 mg, at least 230 mg, or at least 240 mg.

13. The device according to any one of claims 1 to 7, and 10 to 12, wherein the device is suitable for immediate release of Pritelivir, and wherein anti-herpes simplex virus effective concentration EC_{50} of $\geq$ 0.03 µM is measured after 24 hours post-administration of the device in vaginal fluid.

14. A method of treatment or prevention/suppression of an infection with genital herpes caused by herpes simplex virus Type 1 or Type 2, or prevention/suppression of transmission of a genital herpes caused by herpes simplex virus Type 1 or Type 2, or prevention of acquisition of a genital herpes caused by herpes simplex virus Type 1 or Type 2, comprising administering to a subject in need thereof the device according to any of the preceding claims.

15. A process for the manufacture of a device according to any one of the preceding claims comprising the steps of:

    c) Mixing a biostable and biocompatible polymer and Pritelivir;

    d) Injection-molding the mixture obtained in step a).